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PRECIPITIN in gel and radioimmuno-
assays for CEA were first tested by Gold
and his collaborators for the serodiagnosis
of cancer arising in the gut, stomach and
pancreas (Gold and Freedman, 1965;
Thompson et al., 1969). Extensive trials
with modified CEA radioimmunoassays
have indicated that these tests recognize
tumour associated CEA reacting antigens
present in tumours of other origins
(LoGerfo, Krupey and Hansen, 1971;
Moore et al., 1971; Reynoso et al., 1972;
Laurence et al., 1972) as well as in serum
from patients with alcoholic liver disease,
ulcerative colitis and Crohn's disease
(LoGerfo et al., 1971; Moore et al., 1971;
Rule et al., 1972; Moore, Kantrowitz and
Zamcheck, 1972).
While use of the current CEA radio-
immunoassay is accepted by some, its
broad spectrum reactivity lacks the sensi-
tivity necessary to detect early cancer
cases, or to pinpoint the tissue origin of
the CEA reacting molecules (Snyder and
Miller, 1973). To overcome this defect
" CEA fingerprints ' were obtained by
electrofocusing salirnw extracts from tu-
mours and norinal tissues and performing
CEA radioimmunoassays on each fraction.
Profiles from all sources were then com-
pared to determine which peaks could be
designated as normal, neonatal or onco-
foetal antigens capable of reacting with
broad spectrum CEA antisera.
MATERIALS AND METHODS
Freshly obtained specimens were homo-
genized in saline (2: 1 w/v) at 4°C and
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centrifuged at 10,000 g for 20 min. Each
sample was pretreated overnight with 8 mol/l
urea at 4°C and for one hour at 37°C to
allow glycoprotein dissociation. Twenty mil-
ligrams of these crude preparations were
layered on 110 ml sucrose gradient ampholine
electrofocusing columns in 8 mol/l urea
according to the instructions of the manu-
facturer (LKB, Stockholm) and run for
72 hours with 1-5 mA until a constant
current was obtained. Fractions obtained
were monitored for pH, relative protein
content by OD280, and CEA (by the radio-
immunoassay of LoGerfo et al., 1971). CEA
reagents for this assay, the kind gift of the
Research Division of Hoffmann-La Roche
(New Jersey, U.S.A.) were those currently in
use for clinical assays. Duplicate 10 and
100 [lI samples of each tube were dialysed
in the presence of 50 pul normal goat serum
in 5 ml distilled water and then dialysed
extensively against distilled water for 24-36
hours. Controls were treated in the same
fashion.
RESULTS
Earlier experiments have established
the necessity for extensive urea pre-
treatment of saline extracts of tissue for
optimal dissociation and release of glyco-
protein molecules (Goleski, Janowitz and
Rule, 1972). Electrofocusing profiles of
protein, pH and CEA radioimmunoassays
form exquisitely sensitive fingerprints
from essentially crude extracts. All peaks
greater than 50 ng CEA/tube were con-
sidered to contain significant amounts of
CEA activity. Fig. 1 shows the CEA
fingerprint from the saline extract
obtained from a pool of 20 primary2 3 4 5 6 7 8 9
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FIG. 1.-CEA fingerprint of primary carcinoma pool obtained by electrofocusing and CEA radio-
immunoassays. The pH of the major peaks (from left to right) is 3-0, 4-0, 4 5, 5-0, 6-0, 7-0 and
8-0; minor sub-peaks or shoulders occur at pH 2-0, 2-5, 5.5, 6-5, 7-5 and 9-0. Repeatability was
+0-15 pH units.
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FIG. 2.-CEA fingerprint of normal colon. Representative peaks of 8 individual electrofocusing
columns. The pH of the major peaks ( > 100 ng/tube) is 3-5 and 6-5, whereali minor peaks occur
at pH 2-0, 2-5, 4 5, 5 0, 5-5 and 6-5.
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FIG. 3. CEA fingerprint of foetal gut (16 weeks gestation). The pH of the major peaks
(> 100 ng/ tube) is 2-0, 4 0, 5 0, and 6-5; minor peaks occur at pH 7 5, 8-0 and 8-5.
carcinomata of the colon. Seven major
peaks are found, with 6 minor peaks (or
major peak subcomponents). These can be
compared with Fig. 2, which represents
thosepeaks foundinnormal colon obtained
at autopsy or post-operatively in patients
without inflammatory bowel disease. Only
5 peaks contain more than 50 ng/tube
out of a total of 8. Most notably lacking
were those at pH 3 and 4. The 16-week
old foetal gut CEA fingerprint shown in
Fig. 3 contains approximately 6 peaks.
CEA reactivity is most noticeably lacking
at pH 3. Fig. 4 shows the CEA finger-
print of the perchloric acid (PCA) extract
of the pool of colon carcinomata initially
shown in Fig. 1. Lack of clear separation
of CEA reacting peaks, even after exten-
sive urea pretreatment, is shown by the
PCA extract of CEA. This may possibly
be due to irreversible glycoprotein aggre-
gation and/or loss of CEA reacting mole-
cules due to PCA treatment.
Quantitative increases in CEA reacting
molecules, as well as unique pl for all
cancer extracts tested up to this point
indicate that neoplastic fingerprints can
be easily distinguished from those of
normal tissue origin.
DISCUSSION
Broad spectrum CEA radioimmuno-
assay reagents currently in use for clinical
trials have been used in conjunction with
ampholine-urea electrofocusing of tissues
containing CEA activity to produce unique
l
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FiG. 4.-CEA fingerprint of perchloric acid extract of pooled primary carcinomata shown in Fig. 1.
The major peak occurs at pH 3 0; shoulders occur at pH 2-0, 2-5, 3-5 and 4 0. However, refocusing
continuously pulls low levels of CEA reacting materials 50 ng/tube between pH 4-5 and 8-5.
CEA fingerprints. The multiplicity of
peaks obtained with saline extracts of
pooled primary colonic cancers helps
to explain in part the inability of the
present test to identify circulating onco-
foetal antigens of colon origin (Snyder
and Miller, 1973).
The use of CEA fingerprints to differ-
entiate excessive production of normal
colon antigens, as opposed to those of
neoplastic origin, remains a possibility
with certain refinements to this technique.
Likewise, the production of more specific
antisera and antigens should certainly
be attempted, in order to redesign the
current CEA radioimmunoassay. Such
immunochemical engineering would per-
haps eliminate both the false positives
and false negatives at present inherent
in the test and thus provide a test of
great potential diagnostic value.
Supported by NCI-NIH contract num-
ber IG-71-2337.
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